"FDA halts uniQure’s plans for Huntington’s disease gene therapy" was originally created and published by Pharmaceutical ...

Despite the best efforts of modern medicine, Huntington’s disease is a condition that still comes with a tragic prognosis.

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...

Peake relates the story of folk music legend Woody Guthrie, "our greatest advocate," if only by accident. The ...

In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now unclear." ...

The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as it's ...

The London-based medical research company, focused on analysing trial data using neuroscience imaging and biomarkers, said the deal, worth GBP3.5 million over four years, is with a global ...

TAMPA, Fla. (WFLA) — For the first time, scientists have successfully treated someone suffering from Huntington’s disease, a fatal genetic illness with no cure. The Mayo Clinic reports that the ...

The CEO of the drugmaker Uniqure told investors at a private dinner that the Trump White House “doesn’t like all the drama” inside the FDA.

UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...